Transmedics Group Inc
NASDAQ:TMDX
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
70.3
176.11
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TMDX stock under the Base Case scenario is 46.31 USD. Compared to the current market price of 80.61 USD, Transmedics Group Inc is Overvalued by 43%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Transmedics Group Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TMDX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Transmedics Group Inc
Balance Sheet Decomposition
Transmedics Group Inc
Current Assets | 492.5m |
Cash & Short-Term Investments | 330.1m |
Receivables | 90.1m |
Other Current Assets | 72.3m |
Non-Current Assets | 293.1m |
PP&E | 278.7m |
Intangibles | 13.8m |
Other Non-Current Assets | 663k |
Current Liabilities | 60m |
Accounts Payable | 13.1m |
Accrued Liabilities | 44.7m |
Other Current Liabilities | 2.2m |
Non-Current Liabilities | 515.6m |
Long-Term Debt | 508.5m |
Other Non-Current Liabilities | 7.1m |
Earnings Waterfall
Transmedics Group Inc
Revenue
|
401.1m
USD
|
Cost of Revenue
|
-163.1m
USD
|
Gross Profit
|
238m
USD
|
Operating Expenses
|
-206.5m
USD
|
Operating Income
|
31.5m
USD
|
Other Expenses
|
1.2m
USD
|
Net Income
|
32.6m
USD
|
Free Cash Flow Analysis
Transmedics Group Inc
USD | |
Free Cash Flow | USD |
TMDX Profitability Score
Profitability Due Diligence
Transmedics Group Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Score
Transmedics Group Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
TMDX Solvency Score
Solvency Due Diligence
Transmedics Group Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Transmedics Group Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TMDX Price Targets Summary
Transmedics Group Inc
According to Wall Street analysts, the average 1-year price target for TMDX is 134.39 USD with a low forecast of 87.87 USD and a high forecast of 189 USD.
Dividends
Current shareholder yield for TMDX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
TMDX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 148 full-time employees. The company went IPO on 2019-05-02. The company is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The firm has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Heart EXPAND Trial, OCS Heart EXPAND Continued Access Protocol, or CAP, Trial and OCS Heart PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile.
Contact
IPO
Employees
Officers
The intrinsic value of one TMDX stock under the Base Case scenario is 46.31 USD.
Compared to the current market price of 80.61 USD, Transmedics Group Inc is Overvalued by 43%.